Drugs Misuse Regulation 1987
View - Queensland Legislation - Queensland Government
Skip to main content
Site header
Glossary -->
About
Site map
Related links
Contact us
Help
Search
Toggle navigation
Site navigation
Home
In force legislation
Acts as passed
SL as made
Bills
Repealed legislation
Legislative tables
Notifications
Information
Historical information
Search
Feedback
Glossary -->
About
Site map
Related links
Contact us
Help
Table Of Contents
Toggle navigation
View whole SL
Authorising Act
Turn history notes on
Legislative history
Search SL
PDF
A
Results:
match 0 of 0 provisions
Previous Hit
Next Hit
Return to search results
0 hits in page:
First
Last
Drugs Misuse Regulation 1987
Drugs Misuse Regulation 1987
Part 1
Preliminary
pt 1 hdg ins 1996 SL No. 309 s 4
1 Short title
This regulation may be cited as the
Drugs Misuse Regulation 1987 .
2 Dictionary
The dictionary in schedule 9 defines particular words used in this regulation.
s 2 prev s 2 amd 1996 SL No. 309 s 5 (1); om 8 November 1996 RA s 37
pres s 2 (prev s 4) sub 1998 SL No. 348 s 3 (2)
renum 2002 No. 255 s 3
s 2 def
occupier’s notice reloc to sch 9 1998 SL No. 348 s 3 (1)
s 2 def
record of proceedings reloc to sch 9 1998 SL No. 348 s 3 (1)
s 2 def
search warrant reloc to sch 9 1998 SL No. 348 s 3 (1)
s 2 def
supply ins 1996 SL No. 309 s 5 (3)
om 1998 SL No. 348 s 3 (2)
s 2 def
the Act sub 1989 reg pubd gaz 6 May 1989 pp 230–1
om 1996 SL No. 309 s 5 (2)
Part 2
Syringes and dangerous drugs disposal procedures
pt 2 hdg prev pt 2 hdg ins 1996 SL No. 309 s 6
om 2002 SL No. 255 s 4
pres pt 2 hdg (prev pt 3 hdg) ins 1996 SL No. 309 s 11
renum 2002 SL No. 255 s 5 (1)
3 Prescribed procedures for the disposal of hypodermic syringes and needles
For the purposes of section 10 (4A) of the Act , the prescribed procedures for the disposal of a hypodermic syringe or needle are— (a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or
(b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10 (3) of the Act .
s 3 ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5 (2)
amd 2009 SL No. 99 s 3
4 Prescribed procedure for disposal of dangerous drugs
For the purposes of section 125 of the Act , the prescribed procedure for the disposal of a thing is— (a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 3 ; or
(b) in any other case, at the first reasonable opportunity, by giving— (i) such thing; and
(ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;
to an inspector under the
Medicines and Poisons Act 2019 .
s 4 (prev s 10) ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5 (2)
amd 2006 SL No. 71 s 4; 2008 Act No. 4 s 34; 2009 SL No. 99 s 4; amd 2021 SL No. 141
s 93
sch 8
Part 3
Controlled substances
pt 3 hdg (prev pt 4 hdg) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (1)
5 Other act that is a relevant transaction— Act , s 43C (b)
Any act by which a controlled substance is supplied by a person, in or in connection with the person’s business, to anyone else is a relevant transaction for the supply of a controlled substance.
Example—
A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances. The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away. Both the sale and gift of ephedrine are relevant transactions.
Editor’s note—
Under section 43A of the Act —
supply
means give, distribute, sell or supply.
s 5 prev s 5 amd 1996 SL No. 309 s 7
om 2002 SL No. 255 s 4
pres s 5 (prev s 11) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (2)
6 Documents and proof of identity required for supply of a controlled substance or controlled thing— Act , s 43D (1)(a)
(1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (a
recipient ).
(2) The person must, before supplying the substance or thing, obtain from the recipient a document (an
end user declaration ) showing the following information— (a) the recipient’s name and address, and if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;
(b) details of the official document produced by the recipient under subsection (3) as evidence of the recipient’s identity;
(c) the date and number of the written order for the supply of the substance or thing;
(d) the name and quantity of the substance or thing to be supplied;
(e) if a thing is supplied—the serial number or unique identifier of the thing;
(f) the date on which the substance or thing is to be supplied;
(g) the purpose for which the substance or thing is to be supplied.
(3) If the recipient is an individual, the person must, before supplying the substance or thing, require the recipient to produce an official document containing the recipient’s photograph (for example, a passport or driver licence) as evidence of the recipient’s identity.
(4) The person must, immediately the person supplies the substance or thing under the transaction, make an invoice for the supply of the substance or thing showing the following details— (a) the recipient’s name and address;
(b) the recipient’s order number for the supply of the substance or thing;
(c) the date the substance or thing was supplied;
(d) the name and quantity of the substance or thing supplied.
Maximum penalty for subsection (4)—20 penalty units.
s 6 prev s 6 amd 1996 SL No. 309 s 8
om 2002 SL No. 255 s 4
pres s 6 (prev s 12) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (2)
amd 2008 Act No. 4 s 35; 2009 SL No. 99 s 5
6A End user declaration to be given to commissioner of police service— Act , s 43D (1)(d)
(1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (the
recipient ).
(2) The person must, as soon as practicable after obtaining from the recipient the end user declaration mentioned in section 6 (2), give a copy of the end user declaration to the commissioner of the police service.
s 6A ins 2008 Act No. 4 s 36
7 Details about supply of controlled substance or controlled thing to be recorded in register
(1) The following details about a relevant transaction for the supply of a controlled substance or controlled thing must be recorded in the register— (a) the name and address of the recipient and, if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;
(b) the recipient’s order number for the supply of the substance or thing;
(c) the invoice number for the supply of the substance or thing;
(d) if the recipient is— (i) a company—its Australian Company Number; or
(ii) an individual—the type of official document produced under section 6 (3) and the following details about the document— (A) who issued it;
(B) its serial number or other identifying number or mark;
(e) the name and quantity of the substance or thing supplied;
(f) the date the substance or thing was supplied;
(g) the purpose for which the substance or thing was supplied.
(2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance or thing under the transaction.
(3) Nothing in this section prevents the keeping of a single register for the Act and another Act if— (a) the keeping of the single register is not contrary to the other Act; and
(b) the details recorded under subsection (1) are easily identifiable in the single register.
Note—
See section 43D (1)(c) of the Act for the requirement to keep the register.
s 7 prev s 7 sub reg pubd gaz 17 December 1988 pp 2214–15
amd 1996 SL No. 309 s 9
om 2002 SL No. 255 s 4
pres s 7 (prev s 13) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (2)
amd 2008 Act No. 4 s 37; 2012 SL No. 92 s 19
8 Details about loss or theft of controlled substance or controlled thing to be recorded in register
The following details of the reporting to a police officer of the loss or theft of a controlled substance or controlled thing must be recorded in the register— (a) the day and place the report was made;
(b) the name and registered number of the officer to whom the report was made;
(c) the name and quantity of the substance or thing lost or stolen.
s 8 prev s 8 om 1996 SL No. 309 s 10
pres s 8 (prev s 14) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (2)
amd 2008 Act No. 4 s 38
9 Keeping of register, invoice and other documents
(1) This section applies to the register and other documents mentioned in the Act , section 43D (1) and the invoice required under section 6 (4).
(2) A person who supplies a controlled substance or controlled thing under a relevant transaction must keep the register, documents or invoice— (a) at the principal or only place in Queensland where the person engages in relevant transactions; and
(b) for 2 years from the day the person supplied the substance or thing under the transaction.
s 9 (prev s 15) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5 (2)
amd 2008 Act No. 4 s 39
Part 4
Commercial production of industrial cannabis
pt 4 hdg (prev pt 5 hdg) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
Division 1
Preliminary
pt 4 div 1 hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
10 Operation of pt 4 and schs 7 and 8
(1) Divisions 3 to 6 state activities stated persons are authorised to perform for the purposes of part 5B of the Act .
(2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4 , 5 and 6 .
(3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act , the word has the same meaning as in that part, unless a contrary intention appears.
Note—
See section 46 of the Act for definitions for pt 5B of the Act .
s 10 ins 2002 SL No. 255 s 6
amd 2012 SL No. 92 s 20; 2018 Act No. 5
s 135
Division 2
Certified cannabis seed
pt 4 div 2 hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
11 Planting seed— Act , s 46 , def
planting seed
(1) This section states, for section 46 of the Act , definition
planting seed , when cannabis seed is taken to have been harvested from a cannabis plant (a
0.5% THC plant ) with a THC concentration, in the plant’s leaves and flowering heads, of not more than 0.5%.
(2) Cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if— (a) both of the following apply— (i) an authorised person, at the request of the licensee or on the authorised person’s own initiative, arranges for the THC concentration of a representative sample for the seed to be analysed;
(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and
(b) the seed is labelled with the required particulars.
Note—
See section 27C for additional labelling requirements.
(3) Also, cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if— (a) both of the following apply— (i) an authorised person, at the request of the licensee or on the authorised person’s own initiative, authorises another person in writing to arrange for the THC concentration of a representative sample for the seed to be analysed in a NATA accredited laboratory;
(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and
(b) the seed is labelled with the required particulars.
Note—
See section 27C for additional labelling requirements.
(4) Cannabis seed originating in another State, or another country, is taken to have been harvested from a 0.5% THC plant if the recipient licensee— (a) takes reasonable steps to confirm that— (i) a representative sample for the seed has undergone an analysis that is substantially equivalent to an analysis mentioned in subsection (3)(a)(i); and
(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and
(b) labels the cannabis seed with the required particulars.
Note—
See section 27C for additional labelling requirements.
(5) In this section—
authorised person
means—
(a) an inspector; or
(b) another person authorised by the chief executive for the purpose of this section.
representative sample , for cannabis seed, means a representative sample of cannabis leaves and flowering heads taken from the crop from which the seed was harvested.
s 11 ins 2002 SL No. 255 s 6
sub 2018 Act No. 5 s 136
Division 3
Carriers
pt 4 div 3 hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
12 Application of div 3
This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis— (a) a researcher;
(b) a grower;
(c) a DPI researcher;
(d) an inspector;
(e) a seed supplier.
s 12 ins 2002 SL No. 255 s 6
amd 2018 Act No. 5
s 137
13 Supply
(1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned.
(2) The authorisation— (a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and
(b) has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment.
s 13 ins 2002 SL No. 255 s 6
14 Possession
(1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person.
(2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment.
s 14 ins 2002 SL No. 255 s 6
Division 4
DPI researchers
pt 4 div 4 hdg ins 2002 SL No. 255 s 6
15 Supply
A DPI researcher is authorised— (a) to supply class A or class B research cannabis plants and seed to another DPI researcher or a researcher authorised to possess the cannabis plants and seed; and
(b) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher’s supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and
(c) to supply industrial cannabis seed to any of the following— (i) a grower;
(ii) a researcher;
(iii) another DPI researcher;
(iv) a seed handler;
(v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and
(d) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and
(e) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and
(f) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail.
s 15 ins 2002 SL No. 255 s 6
amd 2018 Act No. 5
s 138
16 Production
A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis— (a) industrial cannabis plants and seed; and
(b) class A and class B research cannabis plants and seed.
s 16 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
17 Possession
A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16 — (a) industrial cannabis plants and seed;
(b) class A and class B research cannabis plants and seed;
(c) processed cannabis.
s 17 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
Division 5
Inspectors
pt 4 div 5 hdg ins 2002 SL No. 255 s 6
18 Supply
An inspector is authorised— (a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and
(b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person.
s 18 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
19 Possession
An inspector is authorised— (a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and
(b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed.
s 19 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
Division 6
Other persons
pt 4 div 6 hdg prev pt 4 div 6 hdg ins 2002 SL No. 255 s 6
om 2018 Act No. 5
s 139
pres pt 4 div 6 hdg (prev pt 4 div 7 hdg) ins 2002 SL No. 255 s 6
renum 2018 Act No. 5 s 147
20 Manufacturer
The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product.
s 20 prev s 20 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
om 2018 Act No. 5
s 139
pres s 20 (prev s 23) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
renum 2018 Act No. 5 s 149
21 Analyst
(1) An analyst is authorised to possess— (a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and
(b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis.
(2) In this section—
authorised person
means any of the following—
(a) a researcher;
(b) a grower;
(c) a DPI researcher;
(d) an inspector.
substance
means a substance that an authorised person reasonably believes to be any of the following—
(a) industrial cannabis plants;
(b) class A or class B research cannabis plants;
(c) processed cannabis.
s 21 prev s 21 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
om 2018 Act No. 5
s 139
pres s 21 (prev s 24) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
amd 2018 Act No. 5 s 141
renum 2018 Act No. 5 s 149
22 Family members
(1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if— (a) the licensee is authorised to produce, possess or supply the substance under the Act ; and
(b) the person’s production, possession or supply of the substance is necessary for, or incidental to the licensee’s production, possession or supply of the substance.
(2) In this section—
substance
means any of the following—
(a) class A research cannabis plants;
(b) class A research cannabis seed;
(c) class B research cannabis plants;
(d) class B research cannabis seed;
(e) industrial cannabis plants;
(f) industrial cannabis seed;
(g) processed cannabis.
s 22 prev s 22 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
om 2018 Act No. 5
s 140
pres s 22 (prev s 25) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
renum 2018 Act No. 5 s 149
23 Employees of authorised persons
(1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if— (a) under the Act , the authorised person is authorised to produce, possess, supply or transport the substance; and
(b) the employee’s production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee’s employment or engagement.
(2) In this section—
authorised person
means any of the following—
(a) a licensee;
(b) a carrier;
(c) a DPI researcher;
(d) an inspector;
(e) a manufacturer;
(f) an analyst.
employee
includes agent.
substance
means any of the following—
(a) class A research cannabis plant;
(b) class A research cannabis seed;
(c) class B research cannabis plant;
(d) class B research cannabis seed;
(e) industrial cannabis plant;
(f) industrial cannabis seed;
(g) processed cannabis.
s 23 (prev s 26) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
amd 2018 Act No. 5
s 142
renum 2018 Act No. 5 s 149
Division 7
Record requirements
pt 4 div 7 hdg (prev pt 4 div 7A hdg) ins 2018 Act No. 5 s 132
renum 2018 Act No. 5 s 147
24 Record requirements— Act , s 110E
This division prescribes, for section 110E of the Act , record requirements for the holder of a relevant authority.
s 24 (prev s 26A) ins 2018 Act No. 5 s 132
renum 2018 Act No. 5 s 149
25 Recording information—researchers and growers
(1) A licensee, who is a researcher or a grower, must make a written record of each of the following— (a) the strains or varieties of all cannabis seed in the licensee’s possession;
(b) the strains or varieties of all cannabis plants the licensee is growing;
(c) the source and quantity of all cannabis plants and seed supplied to the licensee;
(d) if the licensee is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11 (4)(a)(ii);
(e) when and by whom cannabis plants or seed were delivered to the licensee;
(f) if cannabis plants or seed is delivered to the licensee by a carrier—the name of the individual who actually delivered the plants or seed;
(g) if the licensee supplies cannabis plants or seed to a carrier for delivery to a person— (i) the name of the individual to whom the plants or seed were given for delivery; and
(ii) the name of the person to whom it is intended the plants or seed be supplied by the licensee;
(h) when cannabis seed is planted by the licensee;
(i) if the licensee supplies cannabis plants or seed to another person (the
recipient ) who is authorised to possess the cannabis plants or seed— (i) the name of the recipient; and
(ii) what the recipient intends to use the cannabis plants or seed for; and
(iii) for cannabis plants or seed that is not processed cannabis—particulars of how the cannabis plants or seed was grown, or otherwise obtained, by the licensee; and
(iv) the date on which the cannabis plants or seed was supplied to the recipient; and
(v) the quantity of cannabis plants or seed supplied to the recipient;
(j) if the licensee disposes of or destroys cannabis plants or seed— (i) the date the cannabis plants or seed is disposed of or destroyed; and
(ii) the method the licensee used to dispose of or destroy the cannabis plants or seed.
(2) The licensee must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the licensee.
s 25 (prev s 26B) ins 2018 Act No. 5 s 132
amd 2018 Act No. 5
s 143
renum 2018 Act No. 5 s 149
26 Recording information—seed handlers
(1) A seed handler must make a written record of each of the following— (a) the source and quantity of all industrial cannabis seed supplied to the seed handler;
(b) when and by whom industrial cannabis seed was delivered to the seed handler;
(c) if industrial cannabis seed is delivered to the seed handler by a carrier—the name of the individual who actually delivered the seed;
(d) if the seed handler is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11 (4)(a)(ii);
(e) if the industrial cannabis is denatured by the seed handler—how, when and by whom the industrial cannabis seed was denatured;
(f) if the seed handler supplies industrial cannabis seed to a carrier for delivery to a person— (i) the name of the person to whom the seed was given for delivery; and
(ii) the name of the person to whom it is intended the seed be supplied by the seed handler;
(g) the name of each person to whom the seed handler supplies industrial cannabis seed.
(2) The seed handler must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the seed handler.
s 26 (prev s 26C) ins 2018 Act No. 5 s 132
amd 2018 Act No. 5
s 144
renum 2018 Act No. 5 s 149
26D [Repealed]
s 26D ins 2018 Act No. 5 s 132
om 2018 Act No. 5
s 145
27 Keeping record of information
(1) A holder of a relevant authority must keep the record of the information until the end of the first of the following periods— (a) if the authority ends—3 years after the authority ends;
(b) if the holder stops being the holder of the authority—2 years after the holder stops being the holder of the authority.
(2) The holder must keep the record in a form that is readily accessible, usable and able to be interpreted.
s 27 prev s 27 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
om 2018 Act No. 5
s 148
pres s 27 (prev s 26E) ins 2018 Act No. 5 s 132
renum 2018 Act No. 5 s 149
Division 7A
Notification requirements
pt 4 div 7A hdg (prev pt 4 div 7B hdg) ins 2018 Act No. 5 s 132
renum 2018 Act No. 5 s 147
27A Notification requirements—researchers and growers
(1) This section prescribes, for section 110F of the Act , notification requirements for a licensee who is a researcher or a grower.
(2) The licensee must give an inspector written notice— (a) of the planting of cannabis seed by the licensee; and
(b) if cannabis plants planted by the licensee will not be harvested—of the following— (i) the plants will not be harvested;
(ii) how the licensee will dispose of or destroy the plants; and
(c) in relation to a crop of industrial cannabis or class B research cannabis plants planted by the licensee—that the crop is ready to be tested for THC concentration.
(3) The licensee must give a notice under this section to an inspector— (a) for a notice mentioned in subsection (2)(a)—within 14 days of the planting of the seed; or
(b) for a notice mentioned in subsection (2)(b)—within 3 months of the planting of the cannabis plants; or
(c) for a notice mentioned in subsection (2)(c)—at least 4 weeks before the licensee intends to harvest the crop.
s 27A (prev s 26F) ins 2018 Act No. 5 s 132
amd 2018 Act No. 5 s 146
renum 2018 Act No. 5 s 149
Division 8
Other provisions
pt 4 div 8 hdg ins 2002 SL No. 255 s 6
27B Prescribed information for research plans— Act , s 54
(1) This section prescribes, for section 54 (2)(d) of the Act , information that must be included in a research plan relating to an application for a researcher licence.
(2) The research plan must— (a) describe the research and associated activities proposed to be carried out under the licence; and
(b) describe the location of all places where the research and associated activities will be carried out; and
(c) identify any risk of non-compliance with the Act that is associated with the research and associated activities; and
(d) describe measures proposed to be implemented to manage all risks mentioned in paragraph (c), including, for example— (i) how the following will be secured— (A) cannabis crops, cannabis seed and equipment associated with the research and associated activities;
(B) information and records associated with the research and associated activities; and
(ii) what security screening protocols will be put in place for the employees, or other persons, dealing with cannabis crops, cannabis seed and equipment associated with the research and associated activities; and
(iii) how the researcher will restrict access, of employees or other persons, to cannabis crops, cannabis seed and equipment associated with the research and associated activities; and
(iv) how cannabis crops, cannabis seed and equipment associated with the research and associated activities will be safely and securely stored, handled or transported; and
(e) contain any additional information stated in a guideline published by the chief executive under subsection (3).
(3) For subsection (2)(e), the chief executive may publish, on the department’s website, a guideline stating additional information that the chief executive reasonably considers is relevant for the management of risks associated with research and associated activities carried out under a researcher licence.
s 27B ins 2018 Act No. 5 s 150
27C Labelling method
(1) This section applies if a provision of this part, or a condition of a licence, requires— (a) cannabis seed to be labelled so as to indicate particular information; or
(b) particular information to otherwise be included on a container, however described, of cannabis seed.
(2) The requirement is complied with only if the information is— (a) either— (i) written or stamped on— (A) the outside of the container in a position where the information can be clearly seen on the container; or
(B) a label that is fixed to the outside of the container in a position where the label can be clearly seen on the container; or
(ii) if, because the seed is being supplied in bulk, subparagraph (i) cannot reasonably be complied with—included in a written notice given to a person to whom the seed is supplied before or when the seed is delivered to the person; and
(b) written in English; and
(c) written in characters that are at least 1.5mm high; and
(d) written in characters that are either— (i) dark print on a light background; or
(ii) light print on dark background.
(3) A notice under subsection (2)(a)(ii) may be fixed to, or form part of, a delivery docket or invoice given to the person to whom the seed is supplied.
s 27C ins 2018 Act No. 5 s 150
28 Fees
The fees payable under the Act are stated in section 28A and schedule 8E .
s 28 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6
amd 2004 SL No. 231 s 14; 2005 SL No. 268 s 14; 2006 SL No. 267 s 14; 2007 SL No. 232 s 14; 2008 SL No. 314 s 14; 2009 SL No. 176 s 17; 2010 SL No. 268 s 7; 2011 SL No. 110 s 14; 2012 SL No. 92 s 21; 2013 SL No. 102 s 16; 2014 SL No. 113 s 16; 2015 SL No. 57 s 16; 2016 SL No. 99 s 14; 2017 SL No. 111 s 16; 2018 SL No. 98 s 16; 2019 SL No. 127 s 17
sub 2020 SL No. 152 s 15; 2021 SL No. 85 s 16; 2022 SL No. 6 s 3
28A Monitoring fees— Act , s 110G
(1) For section 110G (1) of the Act , the monitoring fee for the monitoring of activities performed under a relevant authority is provided for in this section and schedule 8E , item 8.
(2) The fee stated in schedule 8E , item 8 may consist of, or include, an amount for part of an hour that is the equivalent of the relevant proportion of the hourly rate, stated in the schedule, worked out using 15-minute periods (wholly or partly completed).
(3) In addition to the monitoring fee stated in schedule 8E , item 8, the holder of the relevant authority must pay— (a) the fee worked out under subsection (4) for an inspector monitoring the activities to travel between the inspector’s usual place of work and the place where the activities are monitored; and
(b) if, for monitoring the activities, an inspector takes a sample of cannabis for analysis to determine the THC concentration of the sample—the reasonable cost of analysing the sample.
(4) For subsection (3)(a), the fee must be worked out at the rate stated in schedule 8E , item 8 for the time taken for the travel up to a maximum of 2 hours in a day.
s 28A ins 2022 SL No. 6 s 3
amd 2022 SL No. 52
s 16
29 Licence conditions— Act , s 64
(1) The conditions in schedule 8 are prescribed for section 64 (3) of the Act .
(2) Unless otherwise expressly stated, the conditions apply to all licensees.
s 29 ins 2001 SL No. 52 s 3
sub 2002 SL No. 255 s 6
Part 5
Transitional provisions
pt 5 hdg (prev pt 6 hdg) ins 2001 SL No. 174 s 3
renum 2002 SL No. 255 s 5 (1)
amd 2002 SL No. 368 s 3
30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001
(1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the Drugs Misuse Amendment Regulation (No. 2) 2001 (the
amending regulation ), continues to apply in relation to an offence against the Act committed before the commencement of the amending regulation.
(2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made.
s 30 ins 2001 SL No. 174 s 3
31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002
(1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section.
(2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the Drugs Misuse Amendment Regulation (No. 2) 2002 had not been made.
s 31 ins 2002 SL No. 368 s 4
Schedule 1
Dangerous drugs
sections 4 , definition
dangerous drug , 4A , 5 , 6 , 8 , 8A , 9 and 134 of the Act
sch 1 amd reg pubd gaz 17 December 1988 pp 2214–5
om 1996 SL No. 309 s 13
Part 1
Non-steroid drugs
Amphetamine
Cocaine
Heroin
Lysergide
Methylamphetamine
3,4-Methylenedioxymethamphetamine (MDMA)
Paramethoxyamphetamine (PMA)
Paramethoxymethamphetamine (PMMA)
Phencyclidine
Part 2
Steroid drugs
Androisoxazole
Androstenediol
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone (dehydrotestosterone)
Bolenol
Bolmantalate
Calusterone
Chlorandrostenolone
4-Chloromethandienone
Chloroxydienone
Chloroxymesterone (dehydrochloromethyltestosterone)
Clostebol (4-chlorotestosterone)
Danazol
Dehydroepiandrosterone (DHEA)
Dihydrolone
Dimethandrostanolone
Drostanolone
Enestebol
Epitiostanol
Ethyldienolone
Ethylestrenol
Fluoxymesterone
Formebolone (formyldienolone)
Furazabol
4-Hydroxy-19-nortestosterone
Hydroxystenozol
Mebolazine
Mepitiostane
Mesabolone
Mestanolone (androstalone)
Mesterolone
Methandienone
Methandriol
Methenolone
Methylclostebol
Methyltestosterone
Methyltrienolone
Metribolone
Mibolerone
Nandrolone
Norandrostenolone
Norbolethone
Norclostebol
Norethandrolone
Normethandrone
Ovandrotone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
Quinbolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone, other than in implant preparations for growth promotion in animals
Thiomesterone (tiomesterone)
Tibolone
Trenbolone (trienbolone, trienolone), other than in implant preparations for use in animals
Trestolone
Any other anabolic and androgenic steroidal agent
sch 1 (prev 1986 Act No. 36 sch 1)
amd 1996 Act No. 49 s 15
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 3; 2001 SL No. 174 s 4; 2002 SL No. 255 s 7(1); 2008 Act No. 4 s 40; 2009 SL No. 99 s 6; 2013 SL No. 41 s 3; 2014 Act No. 42 ss 23, 24
Schedule 2
Dangerous drugs
sections 4 , definition
dangerous drug , 4A , 5 , 6 , 8 , 8A , 9 and 134 of the Act
Acetorphine
4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET)
4-Acetoxy-N,N-dimethyltryptamine (O-Acetylpsilocin)
Acetyl-alpha-methylfentanyl
N-Acetyl-4-bromo-2,5-dimethoxyphenethylamine (N-Acetyl 2C-B)
Acetyldihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of acetyldihydrocodeine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine.
Acetylmethadol
Acetylmorphine
N-(1-Adamantyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (FUB AKB48)
N-(1-Adamantyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AKB48)
N-(1-Adamantyl)-1-pentyl-indazole-3-carboxamide (APINACA or AKB48)
Adamantyl 1-pentyl-indazole-3-carboxylate (APINAC or AKB57)
N-(1-Adamantyl)-1-pentyl-indole-3-carboxamide (SDB-001)
Alfentanil
Alkoxyamphetamines and bromo-substituted alkoxyamphetamines other than where separately specified
Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines other than where separately specified
Alkylthioamphetamines and substituted alkylthioamphetamines other than where separately specified
Allobarbital
Allylprodine
Alphacetylmethadol
Alpha-Ethylaminopentiophenone (alpha-EAPP)
Alphaethyltryptamine
Alphameprodine
Alphamethadol
Alpha-Methylfentanyl
Alpha-Methylthiofentanyl
Alphamethyltryptamine (AMT)
Alphaprodine
Alpha-Pyrrolidinoheptanophenone (PV8)
Alpha-Pyrrolidinohexanophenone (alpha-PHP)
Alpha-Pyrrolidinovalerophenone (alpha-PVP)
Alphenal
Alprazolam
2-Aminoindane
N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indazole-3-carboxamide (PX-2)
N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indole-3-carboxamide (PX-1)
4-Amino-3-phenylbutanoic acid (Phenibut)
6-(2-Aminopropyl)benzofuran (6-APB)
5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB)
6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB)
Aminorex
Amobarbital
Anileridine
Aprobarbital
Bambuterol
Barbital
Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring
Benzethidine
Benzphetamine (N-Benzyl-N-alpha-dimethylphenethylamine)
Benzylmorphine
N-Benzylpiperazine (BZP)
Betacetylmethadol
Beta-Hydroxy-3-methylfentanyl
Beta-Hydroxyfentanyl
Betameprodine
Betamethadol
Betaprodine
Bezitramide
Bromazepam
4-Bromo-2,5-dimethoxyamphetamine (DOB, 4-Bromo-DMA)
4-Bromo-2,5-dimethoxyphenethylamine (2C-B)
Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropane)
2-Bromomethcathinone
3-Bromomethcathinone
4-Bromomethcathinone
Brotizolam
Bufotenine (5-Hydroxy-N,N-dimethyltryptamine)
Buprenorphine
Butabarbital
Butalbital
Butallylonal
1,4-Butanediol
Butethal
Butonitazene
Butorphanol
1-Butyl-3-(2-methoxybenzoyl)indole (RCS-4(C4) 2-methoxy isomer)
1-Butyl-3-(1-naphthoyl)indole (JWH-073)
Camazepam
Cannabinoids other than tetrahydrocannibinols
Cannabis
N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (ADB CHMICA)
N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (ADB FUBINACA)
N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ADBICA)
N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indazole-3-carboxamide (AB CHMINACA)
N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (AB CHMICA)
N-(1-Carbamoyl-2-methylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA)
N-(1-Carbamoyl-2-methylpropyl)-1-(2-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA 2-fluorobenzyl isomer)
N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AB PINACA)
N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ABICA)
N-(1-Carbamoyl-2-methylpropyl)-1-pentyl-indazole-3-carboxamide (AB PINACA)
[3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB-597)
Carfentanil
Catha edulis (Khat)
Cathine
Cathinone
Chlordiazepoxide
4-Chloroamphetamine
4-Chloro-2,5-dimethoxyamphetamine (DOC)
2-Chloromethcathinone
3-Chloromethcathinone
4-Chloromethcathinone
1-(5-Chloropentyl)-3-(1-naphthoyl)indole (5-Chloro JWH-018)
Chlorphentermine (4-chloro-alpha,alpha-dimethylphenethylamine)
Clenbuterol
Clobazam
Clonazepam
Clonitazene
Clorazepate
Clotiazepam
Cloxazolam
Coca leaf
Codeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 30mg or less of codeine per dosage unit; or
(b) in undivided preparations containing 1% or less of codeine.
Codeine-N-Oxide
Codoxime
N-Cumyl-1-(5-fluoropentyl)-7-azaindole-3-carboxamide (CUMYL-5F-P7AICA)
N-Cumyl-1-(5-fluoropentyl)-indazole-3-carboxamide (CUMYL-5F-PINACA)
N-Cumyl-1-pentyl-indazole-3-carboxamide (CUMYL-PINACA)
4-Cyano-2-dimethylamino-4,4-diphenylbutane
4-Cyano-1-methyl-4-phenylpiperidine
Cyclobarbital
Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB-602)
1-Cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45)
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8)
1-(Cyclohexylmethyl)-3-(4-methoxy-1-naphthoyl)indole (CHM-081)
Cyclopal
Delorazepam
Desomorphine
Desoxypipradrol (2-DPMP)
Dextromoramide
Dextropropoxyphene
Diampromide
Diazepam
3,4-Dichloro-N-2-(dimethylamino)cyclohexyl-N-methylbenzamide (U-47700)
Diethylpropion
Diethylthiambutene
N,N-Diethyltryptamine
Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit
Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of dihydrocodeine.
Dihydroetorphine
Dihydromorphine
Dimenoxadol
Dimepheptanol
Dimethocaine
2,5-Dimethoxyamphetamine (2,5-DMA)
2,5-Dimethoxy-4-ethylamphetamine (DOET)
2,5-Dimethoxy-4-ethylphenethylamine (2C-E)
2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2)
2,5-Dimethoxy-4-iodoamphetamine (DOI)
2,5-Dimethoxy-4-methylamphetamine (DOM)
2,5-Dimethoxy-4-propylphenethylamine (2C-P)
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)
Dimethylamino-1,2-diphenylethane
2-Dimethylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Dibutylone)
N,N-Dimethylamphetamine
1,3-Dimethylamylamine (DMAA or methylhexanamine)
3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6-H-dibenzo(b,d)pyran
1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210)
N,N-Dimethyl-3,4-methylenedioxyamphetamine (MDDM)
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47, 497 C8 homologue)
Dimethylthiambutene
N,N-Dimethyltryptamine
Dioxaphetyl butyrate
Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit
Dipipanone
Drotebanol
Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine
Ephedra spp.
Ephedrine
Erythropoietin (EPO)
Erythroxylum coca
Erythroxylum nova-granatense
Estazolam
Ethchlorvynol
Ethinamate
4-Ethoxyamphetamine
4-Ethoxy-2,5-dimethoxyamphetamine (MEM)
N-Ethylamphetamine
Ethylcathinone (2-ethylamino-1-phenyl-propan-1-one)
Ethyl Loflazepate
Ethylmethylthiambutene
Ethylmorphine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of ethylmorphine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of ethylmorphine.
N-Ethyl-1-phencyclohexylamine
Ethylphenidate
Ethyl 1-(phenylacetyl)-L-prolylglycinate (GVS-111)
Etizolam
Etodesnitazene (Etazene)
Etonitazene
Etonitazepipne
Etonitazepyne
Etorphine
Etoxeridine
Etryptamine
Fencamfamin
Fenethylline (Theophylline-ethylamphetamine)
Fenoterol
Fenproporex (N-2-Cyanoethylamphetamine)
Fentanyl
Flubromazepam
Flubromazolam
Fludiazepam
Flunitazene
Flunitrazepam
2-Fluoroamphetamine
3-Fluoroamphetamine
4-Fluoroamphetamine
(1-(4-Fluorobenzyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144)
2-Fluoromethamphetamine
3-Fluoromethamphetamine
4-Fluoromethamphetamine
2-Fluoromethcathinone
3-Fluoromethcathinone
4-Fluoromethcathinone
1-(5-Fluoropentyl)-3-(1-adamantylamido)indole (STS-135)
(1-(5-Fluoropentyl)-1-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA)
1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201)
1-(5-Fluoropentyl)-3-(4-fluoro-1-naphthoyl)indole (FAM-2201)
(1-(5-Fluoropentyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11; 5-Fluoro UR-144)
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694)
1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
(5-Fluoro JWH-122)
1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole (THJ-2201)
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)
1-(5-Fluoropentyl)-N-(phenylmethyl)-1-indole-3-carboxamide (5-Fluoro SDB-006)
1-(p-Fluoro)phenylpiperazine
Flurazepam
Formoterol other than in metered aerosols for inhalation
Furethidine
Gamma hydroxybutyric acid (GHB)
Glutethimide
Growth Hormone (hGH)
Halazepam
Haloxazolam
Harmaline
Harmalol
Heptabarbital
Hexethal
Hexobarbital
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)
Hydrocodone
Hydromorphinol
Hydromorphone
4-Hydroxybutanoic acid lactone
2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 47,497)
4-Hydroxy-N,N-diethyltryptamine (4-HO-DET)
N-(2-Hydroxyethyl)-alpha-methylbenzeneethanamine
N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-MDA)
4-Hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
4-Hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MIPT)
Hydroxypethidine
5-Hydroxy tryptophan (5-HTP) other than in preparations containing 100mg or less of 5-HTP per dosage unit
Insulin-like Growth Factor-1 (IGF-1)
4-Iodo-2,5-dimethoxyphenethylamine (2C-I)
Isomethadone
Isotonitazene
Ketamine
Ketazolam
Ketobemidone
Lefetamine (N,N-Dimethyl-alpha-phenylphenethylamine)
Levomethorphan
Levophenacylmorphan
Levorphanol
Lophophora (peyote)
Loprazolam
Lorazepam
Lormetazepam
Levomoramide
Lysergamide and N-alkyl derivatives of lysergamide other than lysergide
Lysergic acid
Mazindol
Mecloqualone (3-(2-Chlorophenyl)-2-methyl-4(3H)-quinazolinone)
Medazepam
Mefenorex (N-(3-Chloropropyl)-alpha-methylphenethylamine)
Mephobarbital
Meprobamate
Mescaline (3,4,5-Trimethoxyphenethylamine)
Mesocarb (3-(Alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine)
Metazocine
Methabarbital
Methadone
Methaqualone (2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone)
Methcathinone
Methiopropamine
Methoxetamine
5-Methoxy alphamethyltryptamine (5-MeO-AMT)
4'-Methoxy-alpha-pyrrolidinopropiophenone (MOPPP)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe)
N-(2-Methoxybenzyl)-2,5-dimethoxy-3,4-dimethylphenethylamine (25G-NBOMe)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe)
5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT)
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)
5-Methoxy dimethyltryptamine
4-Methoxymethcathinone (Methedrone)
5-Methoxy-N-methyl-N-allyltryptamine (5-MeO-MALT)
5-Methoxy-3,4-methylenedioxyamphetamine (MMDA)
5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT)
4-Methoxyphenyl-(1-butyl-1H-indol-3-yl)-methanone (RCS-4 (C4))
2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone (JWH-201)
2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)
2-(3-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-302)
Methyl (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-Acetoxy-6a,10b-dimethyl-4,10-dioxo-dodecahydro-2-(3-furyl)-2H-naphtho{2,1-c]pyran-7-caboxylate (Salvinorin A)
4'-Methyl-alpha-pyrrolidinohexanophenone (MPHP)
4'-Methyl-alpha-pyrrolidinopropiophenone (MePPP)
N-Methyl-2-aminoindane
2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)
2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Butylone)
2-Methylamino-1-phenyl-1-butan-1-one (Buphedrone)
2-(Methylamino)-1-phenylpentan-1-one (Pentedrone)
2-Methylamino-1-phenyl-1-propanone
2-(2-Methylaminopropyl)benzofuran (2-MAPB)
5-(2-Methylaminopropyl)benzofuran (5-MAPB)
6-(2-Methylaminopropyl)benzofuran (6-MAPB)
4-Methylaminorex
4-Methyl-N-benzylcathinone (Benzedrone)
Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB CHMICA)
Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3-methylbutanoate (MMB CHMICA)
Methyldesorphine
Methyldihydromorphine
3',4'-Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP)
3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)
5,6-Methylenedioxy-2-aminoindane (MDAI)
3,4-Methylenedioxyamphetamine (MDA)
3',4'-Methylenedioxy-N-benzylcathinone (BMDP)
1-(3,4-Methylenedioxy)-N,N-dimethylcathinone (Dimethylone)
3,4-Methylenedioxyethylamphetamine (MDEA)
1-(3,4-Methylenedioxy)ethylcathinone (Ethylone)
1-(3,4-Methylenedioxy)methcathinone (methylone)
3,4-Methylenedioxypyrovalerone (MDPV)
4-Methylethylcathinone (4-MEC)
3-Methylfentanyl
Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB FUBINACA)
Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3-methylbutanoate (AMB FUBINACA)
Methyl 2-(1-(5-fluoropentyl)-indazole-3-carboxamido)-3-methylbutanoate (5-Fluoro AMB)
Methyl 2-(1-(5-fluoropentyl)-indole-3-carboxamido)-3-methylbutanoate (MMB-2201)
4-Methylmethcathinone
4-Methylmethylamphetamine (4-MMA)
2-Methyl-3-morpholino-1, 1-diphenylpropane carboxylic acid
Methylphenidate
Methylphenobarbital
1-[1-(4-Methylphenyl)cyclohexyl]piperidine
1-Methyl-4-phenylpiperidine-4-carboxylic acid
1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole (AM-1248)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (AM-2233)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(4-methyl-1-naphthoyl)indole (MAM-1220)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220)
N-Methyl-3-piperidyl benzilate
4-Methylthioamphetamine (4-MTA)
3-Methylthiofentanyl
Methyprylon
Metodesnitazene
Metonitazene
Metopon
Midazolam
Mitragyne speciosa (kratom)
Moramide
Morpheridine
Morphine
Morphine methobromide
Morphine-N-oxide
1-[(2-(4-Morpholinyl)ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (A-796260)
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
Myrophine
Nabilone
Nalbuphine
Nalorphine
Naphthalen-1-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FDU-PB-22)
Naphthalen-1-yl 1-(5-fluoropentyl)-indole-3-carboxylate (NM-2201)
Naphthalen-1-yl 1-pentyl-indazole-3-carboxylate (SDB-005)
N-(1-Naphthalenyl)-1-pentyl-indole-3-carboxamide (NNEI)
Naphthoyl indole
Naphthylpyrovalerone (Naphyrone)
Nicocodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of nicocodine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of nicocodine.
Nicodicodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of nicodicodine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of nicodicodine.
Nicomorphine
Nimetazepam
Nitrazepam
Noracymethadol
6-Nor-6-allyl-lysergic acid diethylamide (AL-LAD)
Norcodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of norcodeine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of norcodeine.
Nordazepam
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Opium
Oxazepam
Oxazolam
Oxycodone
Oxymorphone
Papaver bracteatum
Papaver orientale
Papaver somniferum other than the seed thereof which seed has been rendered sterile
Para-Fluorofentanyl
Parahexyl
Pemoline
Pentazocine
Pentobarbital
1-Pentyl-3-(1-adamantoyl)indole (AB-001)
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)
1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)
(1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4)
1-Pentyl-3-(2-methoxybenzoyl)indole (RCS-4 (2-methoxy isomer))
1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
1-Pentyl-3-(1-naphthoyl)indole (JWH-018)
Pethidine
Phenadoxone
Phenampromide
Phenazepam
Phenazocine
Phendimetrazine
Phenmetrazine
Phenobarbital
Phenomorphan
Phenoperidine
Phentermine (alpha,alpha-Dimethylphenethylamine)
1-(1-Phenylcyclohexyl)pyrrolidine (PCPy)
Phenylmethylbarbituric Acid
1-[1-(Phenylmethyl)cyclohexyl]piperidine
4-Phenylpiperidine-4-carboxylic acid ethyl ester
Phenylpiracetam
1-Phenyl-N-propylcyclohexanamine
Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of pholcodine.
Phthalimidopropiophenone
Piminodine
Pinazepam
Pipradol
Piritramide
Pravadoline (WIN 48098)
Prazepam
Probarbital
Proheptazine
Propallylonal
Properidine
Propiram
Propylhexedrine (1-cyclohexyl-2-methylaminopropane)
1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015)
N-Propyl-3,4-methylenedioxyamphetamine (MDPR)
Protonitazene
Psilocin (4-Hydroxy-N,N-dimethyltryptamine)
Psilocybin (O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine)
Pyrovalerone
N-Pyrrolidino protonitazene (Protonitazepyne)
Quazepam
Quinolin-8-yl 1-(cyclohexylmethyl)-indole-3-carboxylate (BB-22)
Quinolin-8-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FUB-PB-22)
Quinolin-8-yl 1-(5-fluoropentyl)-indazole-3-carboxylate (5-Fluoro NPB-22)
Quinolin-8-yl 1-(5-fluoropentyl)-1-indole-3-carboxamide
Quinolin-8-yl 1-(5-fluoropentyl)-indole-3-carboxylate (5-Fluoro PB-22)
Quinolin-8-yl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB)
Quinolin-8-yl 1-pentyl-1-indazole-3-carboxamide (THJ)
Quinolin-8-yl 1-pentyl-indazole-3-carboxylate (NPB-22)
Quinolin-8-yl 1-pentyl-indole-3-carboxylate (PB-22)
Racemethorphan
Racemoramide
Racemorphan
Remifentanil
Reproterol
Salbutamol other than in metered aerosols or dry powder or capsules of dry powder for inhalation
Salvia divinorum
Secobarbital
Sigmodal
Somatotropin
Sufentanil
Talbutal
Temazepam
Terbutaline, other than in metered aerosols for inhalation
Testolactone
Tetrahydrocannabinols including their alkyl homologues other than where separately specified; and their corresponding carboxylic acids
2,2,3,3-Tetramethyl-N'-(2-oxo-(1-(5-fluoropentyl)indolin-3-yliden))-cyclopropanecarbohydrazide
Tetrazepam
Thebacon
Thebaine
Thialbarbital
Thiamylal
1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP)
Thiobarbituric Acid
Thiofentanyl
Thiopental
Tilidine
Triazolam
1-(3-Trifluoromethylphenyl) piperazine (TFMPP)
Trimeperidine
2,4,5-Trimethoxyamphetamine
3,4,5-Trimethoxyamphetamine
Vinbarbital
Vinylbital
Zeranol
Zipeprol (1-(2-Methoxy-2-phenylethyl))-4-(2-hydroxy-3-methoxy-3- phenylpropyl) piperazine
Zolazapam
Zolpidem
sch 2 (prev 1986 Act No. 36 sch 2)
amd 1987 Act No. 53 s 11; 1989 Act No. 34 s 22; 1996 Act No. 49 s 16
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 303 s 3; 1997 SL No. 459 s 4; 1999 SL No. 41 s 3; 2001 SL No. 174 s 5; 2001 SL No. 249 s 3; 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 5; 2003 SL No. 374 s 3; 2005 SL No. 7 s 3
sub 2008 Act No. 4 s 41
amd 2009 SL No. 99 s 6; 2011 SL No. 168 s 3; 2011 SL No. 222 s 3; 2013 SL No. 41 s 4; 2013 SL No. 266 s 3; 2014 Act No. 42 s 24; 2017 SL No. 41 s 3; 2018 SL No. 50 s 3; 2024 SL No. 163 s 3; 2026 Act No. 7
s 11
Schedule 3
Specified quantities for particular dangerous drugs
sections 4A , 8 , 9 , 125 and 134 of the Act
sch 2A ins 2000 Act No. 28 s 26 sch
amd 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 6
om 2008 Act No. 4 s 42
Part 1
Quantities of non-steroid drugs
Dangerous drug
Quantity of dangerous drug
Amphetamine
2.0g
Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring
50.0g
4-Bromo-2,5-dimethoxyamphetamine
0.5g
4-Bromo-2,5-dimethoxyphenethylamine
2.0g
Cannabis
500.0g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0g, 100 plants
Cocaine
2.0g
Codeine
10.0g
N,N-Diethyltryptamine
2.0g
2,5-Dimethoxy-4-Ethylamphetamine (DOET)
2.0g
2,5-Dimethoxy-4-Methylamphetamine
2.0g
N,N-Dimethyltryptamine
2.0g
Fenethylline
2.0g
Fentanyl
0.01g
Gamma hydroxybutyric acid
2.0g
Heroin
2.0g
Hydromorphone
2.0g
Lysergide
0.004g
Methadone
2.0g
Methcathinone
2.0g
5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)
2.0g
2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)
2.0g
4-Methylaminorex
2.0g
Methylamphetamine
2.0g
3,4-Methylenedioxyamphetamine (MDA)
2.0g
3,4-Methylenedioxyethylamphetamine (MDEA)
2.0g
3,4-Methylenedioxymethamphetamine (MDMA)
2.0g
4-Methylthioamphetamine (4-MTA)
2.0g
Moramide
2.0g
Morphine
2.0g
Opium
20.0g
Paramethoxyamphetamine (PMA)
2.0g
Paramethoxymethamphetamine (PMMA)
2.0g
Pethidine
10.0g
Phencyclidine
0.5g
Psilocin
0.10g
Psilocybin
0.10g
Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids
2.0g
3,4,5-Trimethoxyamphetamine (TMA)
2.0g
Part 2
Quantities of steroid drugs
Dangerous drug
Whole weight of dangerous drug
a dangerous drug mentioned in schedule 1 , part 2
50.0g
sch 3 (prev 1986 Act No. 36 sch 3)
amd 1987 Act No. 53 s 12; 1989 Act No. 34 s 23
sub 1990 Act No. 88 s 3 sch
amd 1996 Act No. 49 s 17
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 303 s 4; 1997 SL No. 459 s 5; 1999 SL No. 41 s 4; 2001 SL No. 249 s 4; 2002 SL No. 255 s 7(1)–(2); 2002 SL No. 368 s 7; 2008 Act No. 4 s 43; 2009 SL No. 99 s 7; 2013 SL No. 41 s 5; 2014 Act No. 42 s 25; 2018 SL No. 50
s 4
Schedule 4
Specified quantities for particular dangerous drugs
sections 4A , 8 , 9 and 134 of the Act
Part 1
Quantities of non-steroid drugs
Dangerous drug
Quantity of dangerous drug
Amphetamine
200.0g
Cocaine
200.0g
Heroin
200.0g
Lysergide
0.4g
Methylamphetamine
200.0g
3,4-Methylenedioxymethamphetamine (MDMA)
200.0g
Paramethoxyamphetamine (PMA)
200.0g
Paramethoxymethamphetamine (PMMA)
200.0g
Phencyclidine
50.0g
Part 2
Quantities of steroid drugs
Dangerous drug
Whole weight of dangerous drug
a dangerous drug mentioned in schedule 1 , part 2
5,000.0g
sch 4 (prev 1986 Act No. 36 sch 4)
amd 1996 Act No. 49 s 18
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 6; 2001 SL No. 174 s 6; 2002 SL No. 255 s 7(1); 2008 Act No. 4 s 44; 2008 SL No. 144 s 4; 2009 SL No. 99 s 8; 2013 SL No. 41 s 6; 2014 Act No. 42 s 26
Schedule 5
Dangerous drugs
sections 4A , 124 and 134 of the Act
Alprazolam
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit
Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of dihydrocodeine.
Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit
Estazolam
Ethyl Loflazepate
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Midazolam
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of pholcodine.
Pinazepam
Prazepam
Quazepam
Temazepam
Tetrazepam
Triazolam
Zolazapam
sch 5 (prev 1986 Act No. 36 sch 5)
amd 1987 Act No. 53 s 13; 1996 Act No. 49 s 19
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 7; 2002 SL No. 255 s 7(1), (3)
sub 2008 Act No. 4 s 45
amd 2009 SL No. 99 s 8
Schedule 6
Controlled substances
sections 4 , definition
controlled substance , and 134 of the Act
Substance
Alternative name
Acetaldehyde
Acetic anhydride
N-Acetylanthranilic acid
2-Acetamidobenzoic acid
N-Acetylephedrine
N-Acetylpseudoephedrine
Allylbenzene
3-Phenyl-1-propene or 2-propenyl benzene
4-Allylpyrocatechol
Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime
Alpha-methyl-3,4- methylenedioxyphenylpropanamide
Alpha-methylstyrene
Alpha-phenylacetoacetamide (APAA)
Alpha-phenylacetoacetonitrile (APAAN)
Ammonium formate
Anethole
4-Anilino-N-phenethylpiperidine (ANPP)
4-Anilinopiperidine
Anthranilic acid
2-Aminobenzoic acid
Benzaldehyde
1,3-Benzodioxole
Benzyl bromide
α-Bromotoluene
Benzyl chloride
α-Chlorotoluene
Benzyl cyanide
1-Benzyl-4-piperidone
Boron tribromide
Bromobenzene
Phenylbromide
5-Bromo-1,3-benzodioxole
3,4-Methylenedioxybromobenzene
Bromo safrole
Calcium metal
Chloroephedrine
1-Chlorophenyl-2-aminopropane
Chloropseudoephedrine
Chromic acid
Chromium trioxide
Chromium (VI) oxide
Ephedrine
Ergocristine
Ergometrine
Ergonovine
Ergotamine
Ethanamine
Monoethylamine
Ethyl alpha-phenylacetoacetate (EAPA)
N-Ethylephedrine
Ethyl phenylacetate
Benzeneacetic acid, ethyl ester
N-Ethylpseudoephedrine
Eugenol
Formaldehyde
Formamide
Gamma-Aminobutyric acid (GABA)
4-Aminobutanoic acid
Helional
Hydriodic acid
Hydrogen iodide solution
Hydrobromic acid
Hydrogen bromide solution
4-Hydroxybutanal
4-Hydroxybutyraldehyde
4-Hydroxybutanoic acid nitrile
4-Hydroxybutyronitrile
1-Hydroxycyclopentyl-(o-chlorophenyl)-ketone N-methylimine
4-Hydroxypentanoic acid
Gamma-Hydroxyvaleric acid
4-Hydroxypentanoic acid lactone
Gamma-valerolactone
2-Hydroxytetrahydrofuran
Tetrahydro-2-furanol
Hypophosphorous acid
Phosphinic acid
Iodine
Isosafrole
5-(1-Propenyl)-1,3-benzodioxole
Lithium aluminium hydride
Lithium metal
Magnesium metal
Mandelic acid
Alpha-Hydroxyphenylacetic acid
Mercuric chloride
Mercury bichloride or Mercury (II) chloride
Mercury metal
N-Methylalanine
Methyl alpha-phenylacetoacetate (MAPA)
Methylamine
Aminomethane or Monomethylamine
Methylammonium salts
3,4-Methylenedioxphenylacetic acid
3,4-Methylenedioxyphenylacetonitrile
3,4-Methylenedioxyphenyl-2-nitropropene
3,4-Methylenedioxyphenyl-2-propanone
N-Methylephedrine
N-Methylformamide
Methyl 3-[3’,4’-(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG)
Methyl phenylacetate
Benzeneacetic acid, methyl ester
Methyl 3-phenyl-2-methyl glycidate
P2P methyl glycidic acid, methyl ester
N-Methylpseudoephedrine
Nitroethane
Nitromethane
Norpseudoephedrine
Palladium
Paramethoxyphenyl-2-propanone
N-(2-Phenethyl)-4-piperidinone (NPP)
Phenylacetamide
Phenylacetic acid
Phenylacetonitrile
Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile
L-Phenylacetylcarbinol
L-PAC or 1-Hydroxy-1-phenyl-2-propanone
Phenylacetyl chloride
1-Phenyl-2-bromopropane
1-Phenyl-2-chloropropane
1-Phenyl-2-iodopropane
1-Phenyl-2-methylaminopropane
1-Phenyl-2-nitropropene
4-Phenyl-3-oxobutanoic acid
4-Phenylacetoacetic acid
2-Phenylpropanal
Hydratropaldehyde
1-Phenyl-1,2-propanedione
Benzoyl methyl ketone
1-Phenyl-2-propanol
Phenylpropanolamine
Norephedrine
1-Phenyl-1-propanone
Phenyl ethyl ketone or Propiophenone
1-Phenyl-2-propanone
Benzyl methyl ketone or Phenylacetone
1-Phenyl-2-propanone bisulphite
1-Phenyl-2-propanone oxime
Phosphorous acid
Phosphonic Acid
Phosphorus (red or white)
Piperidine
4-Piperidone
Piperonal
Heliotropine or 3,4-Methylenedioxybenzaldehyde
Platinum metal
Potassium metal
Propionic anhydride
Pseudoephedrine
Pyridine
2-Pyrrolidone
Gamma-butyrolactam
Raney nickel
Safrole
5-(2-Propenyl)-1,3-benzodioxide
Sassafras oil
Sodium bis(2-methoxyethoxy) aluminium hydride
Sodium borohydride
Sodium cyanoborohydride
Sodium metal
Sodium 2-methyl-3-(3,4-methylenedioxy)phenyl-glycidate
Sodium 2-methyl-3-phenyl glycidate
Thionyl chloride
Thorium
P-Tosyl 3,4-methylenedioxyphenyl-2-propanol
P-Tosyl MDP2Pol
P-Tosyl phenyl-2-propanol
P-Tosyl P2Pol
Trans-beta-methylstyrene
sch 6 (prev 1986 Act No. 36 sch 6)
ins 1995 Act No. 18 s 8
amd 1996 Act No. 49 s 20
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 8; 2002 SL No. 255 s 7(1)
sub 2006 SL No. 71 s 5
amd 2009 SL No. 99 s 9; 2018 SL No. 169
s 4 ; 2026 SL No. 39
s 3 ; 2026 Act No. 7
s 12
Schedule 7
Conditions for particular persons authorised under part 4
section 10 (2)
sch 7 hdg ins 1998 SL No. 348 s 5
1 DPI researcher
A DPI researcher must— (a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and
(b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and
(c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and
(d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher’s possession or under the researcher’s control locked in a secure place when not otherwise required— (i) for use for planting; or
(ii) to be supplied to another person; and
(e) keep a register that includes the following information— (i) the varieties or strains of cannabis plants and cannabis seed under the researcher’s control;
(ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives;
(iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher;
(iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed;
(v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else— (A) the name of the person to whom the plants or seed were given for delivery; and
(B) the name of the person to whom it is intended the plants or seed be supplied by the researcher.
sch 7 s 1 prev sch 1 s 1 ins 1998 SL No. 348 s 5
sub 2002 SL No. 255 s 8
amd 2009 SL No. 99 s 10; 2018 Act No. 5 s 133
om 2018 Act No. 5 s 151(1)
pres sch 1 s 1 (prev sch 1 s 2) ins 1998 SL No. 348 s 5
sub 2002 SL No. 255 s 8
renum 2018 Act No. 5 s 151(4)
2 Inspector
An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person.
sch 7 s 2 (prev sch 7 s 3) ins 1998 SL No. 348 s 5
sub 2002 SL No. 255 s 8
renum 2018 Act No. 5 s 151(4)
3 Analyst
(1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration.
(2) The analyst must analyse the substance in a NATA accredited laboratory.
(3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration.
(4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance.
(5) In this section—
substance
means a substance the analyst reasonably believes to be any of the following—
(a) industrial cannabis plants;
(b) class A or class B research cannabis plants;
(c) processed cannabis.
sch 7 s 3 (prev sch 7 s 5) ins 2002 SL No. 255 s 8
amd 2018 Act No. 5 s 151(2)–(3)
renum 2018 Act No. 5 s 151(4)
4 [Repealed]
sch 7 s 4 ins 1998 SL No. 348 s 5
amd 1999 SL No. 235 s 3
sub 2002 SL No. 255 s 8
amd 2018 Act No. 5 s 133
om 2018 Act No. 5 s 151(1)
sch 7 sub 2002 SL No. 255 s 8
Schedule 8
Licence conditions
section 29 (1)
Part 1
General conditions
1 A licensee must keep cannabis seed in the licensee’s possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee’s licence.
2 As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with.
3 A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure— (a) if the seed is cannabis seed harvested from an industrial cannabis plant—the seed is labelled so as to describe the seed as cannabis seed harvested from an industrial cannabis plant; or
(b) if the seed is to be supplied as planting seed—the seed is labelled with the required particulars.
Note—
See section 27C for additional labelling requirements.
Part 2
Particular conditions for researcher licences
4 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the researcher that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more.
5 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%.
6 A researcher must carry out activities under the researcher’s licence in accordance with the approved research plan for the licence.
Part 3
Particular conditions for grower licences
7 A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the grower that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%.
Part 4
Particular conditions for seed handler licences
8 A seed handler must—
(a) ensure all industrial cannabis seed in the possession of the seed handler is labelled to state—
(i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or
(ii) if the seed is intended to be used or supplied as planting seed—the required particulars; and
Note—
See section 27C for additional labelling requirements.
(b) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not escape from the packaging or be accidentally released or tampered with.
sch 8 ins 1998 SL No. 348 s 5
sub 1999 SL No. 235 s 4; 2000 SL No. 234 s 3; 2002 SL No. 255 s 8
amd 2018 Act No. 5 s 134
sub 2018 Act No. 5
s 152
Schedule 8A
Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act
sections 9A , 9B , 9C , 9D and 134 of the Act
Part 1
Substances that include their salts, derivatives and stereo-isomers
1 In this part, a reference to a substance includes a reference to— (a) a salt, derivative or stereo-isomer of the substance; and
(b) a salt of a derivative or stereo-isomer of the substance.
Substance
Alternative name
Gross weight
Acetaldehyde
0.1g
N-Acetylanthranilic acid
2-Acetamidobenzoic acid
0.1g
N-Acetylephedrine
0.1g
N-Acetylpseudoephedrine
0.1g
Allylbenzene
3-Phenyl-1-propene or 2-propenyl benzene
0.1g
4-Allylpyrocatechol
0.1g
Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime
0.1g
Alpha-methyl-3,4- methylenedioxyphenylpropanamide
0.1g
Alpha-methylstyrene
0.1g
Alpha-phenylacetoacetamide (APAA)
0.1g
Alpha-phenylacetoacetonitrile (APAAN)
0.1g
Ammonium formate
0.1g
Anethole
0.1g
4-Anilino-N-phenethylpiperidine (ANPP)
0.1g
4-Anilinopiperidine
0.1g
Anthranilic acid
2-Aminobenzoic acid
0.1g
Benzaldehyde
0.1g
1,3-Benzodioxole
0.1g
Benzyl bromide
α-Bromotoluene
0.1g
Benzyl chloride
α-Chlorotoluene
0.1g
Benzyl cyanide
0.1g
1-Benzyl-4-piperidone
0.1g
Boron tribromide
0.1g
Bromobenzene
Phenylbromide
0.1g
5-Bromo-1,3-benzodioxole
3,4-Methylenedioxybromobenzene
0.1g
Bromo safrole
0.1g
Chloroephedrine
0.1g
1-Chlorophenyl-2-aminopropane
0.1g
Chloropseudoephedrine
0.1g
Chromic acid
0.1g
Chromium trioxide
Chromium (VI) oxide
0.1g
Ephedrine
0.1g
Ergocristine
0.1g
Ergometrine
Ergonovine
0.1g
Ergotamine
0.1g
Ethanamine
Monoethylamine
0.1g
Ethyl alpha-phenylacetoacetate (EAPA)
0.1g
N-Ethylephedrine
0.1g
Ethyl phenylacetate
Benzeneacetic acid, ethyl ester
0.1g
N-Ethylpseudoephedrine
0.1g
Eugenol
0.1g
Formaldehyde
0.1g
Formamide
0.1g
Gamma-Aminobutyric acid (GABA)
4-Aminobutanoic acid
0.1g
Helional
0.1g
4-Hydroxybutanal
4-Hydroxybutyraldehyde
0.1g
4-Hydroxybutanoic acid nitrile
4-Hydroxybutyronitrile
0.1g
1-Hydroxycyclopentyl-(o-chlorophenyl)-ketone N-methylimine
0.1g
4-Hydroxypentanoic acid
Gamma-Hydroxyvaleric acid
0.1g
4-Hydroxypentanoic acid lactone
Gamma-valerolactone
0.1g
2-Hydroxytetrahydrofuran
Tetrahydro-2-furanol
0.1g
Hypophosphorous acid
Phosphinic acid
0.1g
Isosafrole
5-(1-Propenyl)-1,3-benzodioxole
0.1g
Lithium aluminium hydride
0.1g
Mandelic acid
Alpha-Hydroxyphenylacetic acid
0.1g
Mercuric chloride
Mercury bichloride or Mercury (II) chloride
0.1g
N-Methylalanine
0.1g
Methyl alpha-phenylacetoacetate (MAPA)
0.1g
Methylamine
Aminomethane or Monomethylamine
0.1g
Methylammonium salts
0.1g
3,4-Methylenedioxphenylacetic acid
0.1g
3,4-Methylenedioxyphenylacetonitrile
0.1g
3,4-Methylenedioxyphenyl-2-nitropropene
0.1g
3,4-Methylenedioxyphenyl- 2-propanone
0.1g
N-Methylephedrine
0.1g
N-Methylformamide
0.1g
Methyl 3-[3’,4’-(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG)
0.1g
Methyl phenylacetate
Benzeneacetic acid, methyl ester
0.1g
Methyl 3-phenyl-2-methyl glycidate
P2P methyl glycidic acid, methyl ester
0.1g
N-Methylpseudoephedrine
0.1g
Nitroethane
0.1g
Nitromethane
0.1g
Norpseudoephedrine
0.1g
Palladium
0.1g
Paramethoxyphenyl-2-propanone
0.1g
N-(2-Phenethyl)-4-piperidinone (NPP)
0.1g
Phenylacetamide
0.1g
Phenylacetic acid
0.1g
Phenylacetonitrile
Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile
0.1g
L-Phenylacetylcarbinol
L-PAC or 1-Hydroxy-1-phenyl-2-propanone
0.1g
Phenylacetyl chloride
0.1g
1-Phenyl-2-bromopropane
0.1g
1-Phenyl-2-chloropropane
0.1g
1-Phenyl-2-iodopropane
0.1g
1-Phenyl-2-methylaminopropane
0.1g
1-Phenyl-2-nitropropene
0.1g
4-Phenyl-3-oxobutanoic acid
4-Phenylacetoacetic acid
0.1g
2-Phenylpropanal
Hydratropaldehyde
0.1g
1-Phenyl-1,2-propanedione
Benzoyl methyl ketone
0.1g
1-Phenyl-2-propanol
0.1g
Phenylpropanolamine
Norephedrine
0.1g
1-Phenyl-1-propanone
Phenyl ethyl ketone or Propiophenone
0.1g
1-Phenyl-2-propanone
Benzyl methyl ketone or Phenylacetone
0.1g
1-Phenyl-2-propanone bisulphite
0.1g
1-Phenyl-2-propanone oxime
0.1g
Piperidine
0.1g
4-Piperidone
0.1g
Piperonal
Heliotropine or 3,4-Methylenedioxybenzaldehyde
0.1g
Propionic anhydride
0.1g
Pseudoephedrine
50g or 1L
Pyridine
0.1g
2-Pyrrolidone
Gamma-butyrolactam
0.1g
Raney nickel
0.1g
Safrole
5-(2-Propenyl)-1,3-benzodioxide
0.1g
Sassafras oil
0.1g
Sodium bis(2-methoxyethoxy) aluminium hydride
0.1g
Sodium borohydride
0.1g
Sodium cyanoborohydride
0.1g
Sodium 2-methyl-3-(3,4-methylenedioxy)phenyl-glycidate
0.1g
Sodium 2-methyl-3-phenyl glycidate
0.1g
Thionyl chloride
0.1g
Thorium
0.1g
P-Tosyl 3,4-methylenedioxyphenyl-2-propanol
P-Tosyl MDP2Pol
0.1g
P-Tosyl phenyl-2-propanol
P-Tosyl P2Pol
0.1g
Trans-beta-methylstyrene
0.1g
Part 2
Substances that do not include their salts, derivatives and stereo-isomers
2 In this part, a reference to a substance does not include a reference to— (a) a salt, derivative or stereo-isomer of the substance; and
(b) a salt of a derivative or stereo-isomer of the substance.
Substance
Alternative name
Gross weight
Acetic anhydride
0.1g
Calcium metal
0.1g
Hydriodic acid
Hydrogen iodide solution
0.1g
Hydrobromic acid
Hydrogen bromide solution
0.1g
Iodine
0.1g
Lithium metal
25g
Magnesium metal
0.1g
Mercury metal
0.1g
Phosphorous acid
Phosphonic Acid
0.1g
Phosphorus (red or white)
0.1g
Platinum metal
0.1g
Potassium metal
0.1g
Sodium metal
0.1g
sch 8A ins 2006 SL No. 71 s 6
amd 2008 Act No. 4 s 46; 2013 Act No. 14 s 50; 2018 SL No. 169 s 5; amd 2026 SL No. 39
s 4 ; 2026 Act No. 7
s 13
Schedule 8B
Things specified for ss 9A, 9B, 9C and 9D, and prescribed for s 134, of Act
sections 9A , 9B , 9C , 9D and 134 of the Act
1 hydrogen sulfide gas cylinder
2 hydrogen chloride gas cylinder
3 hydrogen gas cylinder
4 ammonia gas cylinder
5 condenser
6 distillation head
7 heating mantle
8 manual or mechanical pill press, including a pill press under repair, a modification of a pill press and parts for a pill press
9 reaction vessel, including a reaction vessel under repair or a modification of a reaction vessel
10 rotary evaporator
11 splash head, including a splash head under repair or parts for a splash head
sch 8B ins 2006 SL No. 71 s 6
amd 2008 Act No. 4 s 47; 2009 SL No. 99 s 11; 2013 Act No. 14 s 51; 2018 SL No. 169
s 6
Schedule 8C
Prohibited combinations of items
sections 10B and 134 of the Act
1 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and
(b) hypophosphorous acid; and
(c) iodine.
2 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and
(b) hydriodic acid; and
(c) phosphorous (red or white).
3 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and
(b) lithium metal; and
(c) ammonia gas.
sch 8C ins 2006 SL No. 71 s 6
Schedule 8D
Relevant dangerous drugs
sections 131 and 134 of the Act
amphetamine
methylamphetamine
sch 8D ins 2006 SL No. 71 s 6
Schedule 8E
Fees
sections 28 and 28A
Fee units
1
Application fee for a researcher licence (Act, s 54(2)(a))
1,942.95
2
Application fee for a grower licence (Act, s 54(2)(a))
1,304.95
3
Application fee for a seed handler licence (Act, s 54(2)(a))
435.65
4
Licence renewal fee for a researcher licence (Act, s 65(2)(d)(i))
1,572.85
5
Licence renewal fee for a grower licence (Act, s 65(2)(d)(i))
1,059.95
6
Licence renewal fee for a seed handler licence (Act, s 65(2)(d)(i))
435.65
7
Application fee for amendment of a licence or a condition of a licence (Act, s 70(2))
294.95
8
Monitoring of an activity performed under a relevant authority, for each hour involved (Act, s 110G(1))
322.05
Notes—
1 See section 28A (2) in relation to a fee for part of an hour.
2 See section 28A (3) and (4) in relation to the fee for an inspector’s travel and the cost of analysis of a sample of cannabis for monitoring an activity.
sch 8E ins 2022 SL No. 6
s 4
amd 2022 SL No. 52 s 17
Schedule 9
Dictionary
section 2
analyst
means a person who is authorised under the
Medicines and Poisons Act 2019
to use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration.
sch 9 def
analyst sub 2021 SL No. 141
s 93
sch 8
approved research plan , for a researcher licence, means a research plan that forms part of the licence under section 63 (4) of the Act as amended in accordance with the Act .
sch 9 def
approved research plan ins 2018 Act No. 5 s 153(2)
carrier
means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea.
condenser
means a cooling device for converting gases or vapours to liquid or solid form.
sch 9 def
condenser ins 2006 SL No. 71 s 7
consigned
includes addressed.
consigned cannabis
means any of the following—
(a) industrial cannabis plants;
(b) industrial cannabis seed;
(c) class A research cannabis;
(d) class B research cannabis;
(e) processed cannabis.
distillation head
means an apparatus that—
(a) fits on top of a reaction vessel or a vessel that serves the same purpose as a reaction vessel; and
(b) connects to a condenser; and
(c) is suitably angled to allow vapour to flow downwards into a collection vessel.
sch 9 def
distillation head ins 2006 SL No. 71 s 7
DPI researcher
means a public service officer—
(a) who is employed in the department within which the
Biosecurity Act 2014
is administered; and
(b) whose duties include plant breeding; and
(c) who is authorised by the chief executive in writing to perform activities stated in part 4 , division 4 .
sch 9 def
DPI researcher amd 2016 SL No. 75
s 129 sch 12
gas cylinder
means a cylinder or other thing that—
(a) is used for storing gas in any form; and
(b) has a storage capacity of less than 1 tonne.
sch 9 def
gas cylinder ins 2018 SL No. 169 s 7
heating mantle
means a device designed or adapted to heat a reaction vessel or a vessel that serves the same purpose as a reaction vessel.
sch 9 def
heating mantle ins 2006 SL No. 71 s 7
NATA
means the National Association of Testing Authorities, Australia ABN 59 004 379 748.
sch 9 def
NATA ins 2018 Act No. 5 s 153(2)
NATA accredited laboratory
means a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis.
sch 9 def
NATA accredited laboratory ins 2018 Act No. 5 s 153(2)
occupier’s notice ...
sch 9 def
occupier’s notice reloc 1998 SL No. 348 s 3(1)
om 2002 SL No. 255 s 8
recipient licensee , in relation to cannabis seed originating in another State or another country, means the licensee who first takes possession of the seed after it enters the State.
sch 9 def
recipient licensee ins 2018 Act No. 5 s 153(2)
record of proceedings ...
sch 9 def
record of proceedings reloc 1998 SL No. 348 s 3(1)
om 2002 SL No. 255 s 8
required particulars
means—
(a) a report number, or other identifying information, for the report containing the results mentioned in section 11 (2)(a)(ii), (3)(a)(ii) or (4)(a)(ii); and
(b) the words ‘planting seed’; and
(c) the words ‘This seed was harvested from a cannabis plant with a THC concentration in the plant’s leaves and flowering heads, of not more than 0.5%’; and
(d) for cannabis seed originating in the State—the name and licence number of the grower who produced the seed; and
(e) for cannabis seed originating in another State or another country—the name of— (i) the State or other country; and
(ii) the recipient licensee.
sch 9 def
required particulars ins 2018 Act No. 5 s 153(2)
search warrant ...
sch 9 def
search warrant reloc 1998 SL No. 348 s 3(1)
om 2002 SL No. 255 s 8
seed supplier ...
sch 9 def
seed supplier om 2018 Act No. 5 s 153(1)
splash head
means an apparatus that fits between a reaction vessel, or a vessel that serves the same purpose as a reaction vessel, and a condenser and stops a heated substance contaminating the distillate.
sch 9 def
splash head ins 2006 SL No. 71 s 7
standard THC material
means THC of a known purity.
supply —
(a) for part 3 , see section 43A of the Act ; or
(b) for part 4 , does not include administer.
sch 9 ins 1998 SL No. 348 s 5
sub 2002 SL No. 255 s 8
from top.html -->
Site footer
Copyright
Disclaimer
Privacy
Right to information
-->
Accessibility
Jobs in Queensland Government
Other languages
© The State of Queensland (Office of the Queensland Parliamentary Counsel) 2014-2026 (Ver. 2.7.30-7865 Rev. )
Queensland Government
-->